Restrospective Analysis of MACE in Patients Treated With Drug-elluting Balloons.

N/ANot Yet RecruitingNCT06972225

Olivier F. Bertrand1,500 enrolled

Overview

Retrospective analysis of data collected in an institutional database of coronary interventions with use of drug-eluting balloons, with a prospective follow-up for major adverse cardiovascular events and living status.

Study Type

OBSERVATIONAL

Enrollment

1,500

Conditions

Coronary Arterial Disease (CAD)Restenosis, Coronary Bifurcation Coronary Disease

Interventions

DEBDEVICE

Use of DEB to treat coronary lesions

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults (\>=18 years of age) * Who underwent a coronary angioplasty with drug-eluting balloon between January 2010 and December 2025 * Identified in the institutional procedure database Exclusion Criteria: * Incomplete or non-available data on the post-procedural clinical follow-up * Procedures where other devices were used in combination with drug-eluting balloons.

Locations (1)

IUCPQ

Québec, Quebec, Canada

Outcomes

Primary Outcomes

Major Adverse Cardiovascular Events

defined as: * Cardiovascular death * Myocardial infarction * Target vessel revascularization * Cerebrovascular event * Hospitalization due to heart failure

Time frame: within 10 years of inclusion

Central Contacts

Michele Jadin

CONTACT

418-6568711 michele.jadin@criucpq.ulaval.ca

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.